NCT03960645 - Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

July 21, 2022

Study Completion Date

August 18, 2022

Conditions

HIV-1-infection

Interventions

DRUG

B/F/TAF

50/200/25 mg FDC tablet administered orally once daily without regard to food.

Trial Locations (8)

Instituto Dominicano de Estudios Virologics (IDEV), Santo Domingo

Thai Red Cross AIDS Research Centre, Pathumwan

Faculty of Medicine Siriraj Hospital, Bangkok Noi

Bamrasnaradura Infectious Diseases Institute, Nonthaburi

Triple O Research Institute, P.A., West Palm Beach

Midway Immunology and Research Center, Ft. Pierce

Faculty of Medicine-Khon Kaen University, Khon Kaen

Research Institute for Health Sciences, Chiang Mai University, Nonthaburi